The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...
The Chronic Pruritus Market is making significant strides, fueled by innovative treatment approaches and ongoing research ...
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year ...
Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ...
Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...
With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...
The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer ...
The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...
Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...
Insights shed light on what the approval means for providers and their patients affected by this neurodegenerative retinal ...
The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback